A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
NCT ID: NCT00303589
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
313 participants
INTERVENTIONAL
2005-12-31
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
beta-lactam
750mg iv q8h
2
beta-lactam
1500mg iv q8h
3
Standard care
As prescribed
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard care
As prescribed
beta-lactam
750mg iv q8h
beta-lactam
1500mg iv q8h
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* skin or skin structure infection requiring hospitalization;
* clinical diagnosis of a skin or skin structure infection caused by bacteria known or suspected to be susceptible to the randomized study treatment;
* material from site of infection is clinically purulent or seropurulent.
Exclusion Criteria
* known or suspected concomitant bacterial infection requiring antibiotic treatment;
* skin infection or chronic non-healing ulcer of \> 2 weeks duration;
* patients in whom surgery is the primary treatment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Mobile, Alabama, United States
Melbourne, Florida, United States
Miami Beach, Florida, United States
Detroit, Michigan, United States
Detroit, Michigan, United States
Minneapolis, Minnesota, United States
Winston-Salem, North Carolina, United States
Buenos Aires, , Argentina
Buenos Aires, , Argentina
Buenos Aires, , Argentina
Buenos Aires, , Argentina
Ciudadela, , Argentina
Córdoba, , Argentina
Córdoba, , Argentina
El Palomar, , Argentina
Entre Ríos, , Argentina
Granadero Baigorria, , Argentina
Merlo, , Argentina
Neuquén, , Argentina
Rosario, , Argentina
Rosario, , Argentina
Santa Fe, , Argentina
Pleven, , Bulgaria
Plovdiv, , Bulgaria
Sofia, , Bulgaria
Varna, , Bulgaria
Tallinn, , Estonia
Tallinn, , Estonia
Tartu, , Estonia
Lübeck, , Germany
Mainz, , Germany
München, , Germany
Münster, , Germany
Budapest, , Hungary
Budapest, , Hungary
Győr, , Hungary
Liepāja, , Latvia
Riga, , Latvia
Riga, , Latvia
Riga, , Latvia
Kaunas, , Lithuania
Klaipėda, , Lithuania
Vilnius, , Lithuania
Vilnius, , Lithuania
Vilnius, , Lithuania
La Victoria, Lima, , Peru
Lima, , Peru
Lima, , Peru
Lima, , Peru
Bucharest, , Romania
Bucharest, , Romania
Cluj-Napoca, , Romania
Constanța, , Romania
Târgu Mureş, , Romania
Benoni, , South Africa
Cape Town, , South Africa
Middleburg, , South Africa
Port Elizabeth, , South Africa
Pretoria, , South Africa
Sommerset West, , South Africa
Themba, , South Africa
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WI18274
Identifier Type: -
Identifier Source: org_study_id